Samantha Buccina, PA
Medical · Jefferson Hills, PANPI 1477028249
Payments from drug & device makers
Across 80 payments — averaging $19.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$376
- AbbVie$351
- Bayer$263
- AstraZeneca$137
- Astellas Pharma US Inc$78
- Pfizer$57
- plus $307 from 15 others
What the payments were for
- Food & beverage$1,49195%
- Education$785%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 31 | $376 |
| AbbVie | 13 | $351 |
| Bayer | 10 | $263 |
| AstraZeneca | 2 | $137 |
| Astellas Pharma US Inc | 1 | $78 |
| Pfizer | 4 | $57 |
| Boehringer Ingelheim | 3 | $45 |
| Merck | 2 | $36 |
| Genentech USA, Inc. | 1 | $29 |
| Lilly USA, LLC | 2 | $28 |
| Edwards Lifesciences | 1 | $22 |
| Corium, LLC | 1 | $18 |
| GSK | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Novartis | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Ultragenyx Pharmaceutical Inc. | 1 | $13 |
| Amgen | 1 | $12 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,569 in reported general payments places this provider in the 75th percentile of 2,594 medical providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 77 | $69,248 |
| OzempicSemaglutide | 54 | $62,284 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 79 | $62,230 |
| JardianceEmpagliflozin | 34 | $44,519 |
| RybelsusSemaglutide | 12 | $14,866 |
| MyrbetriqMirabegron | 14 | $10,895 |
| VascepaIcosapent Ethyl | 14 | $5,664 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 79 | $2,266 |
| Atorvastatin Calcium | 263 | $2,097 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 22 | $1,865 |
| Potassium Chloride | 56 | $1,494 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $1,421 |
| Gabapentin | 113 | $1,349 |
| Levothyroxine Sodium | 125 | $1,315 |
| Pantoprazole Sodium | 128 | $1,283 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $376 | $77,15066 claims |
| PfizerEliquis | $57 | $69,24877 claims |
| GSKTrelegy Ellipta | $17 | $62,23079 claims |
| Boehringer IngelheimJardiance | $45 | $44,51934 claims |
| Astellas Pharma US IncMyrbetriq | $78 | $10,89514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,594 medical providers in Pennsylvania.
Other medical in Jefferson Hills
- Jacqueline KernaghanSpringfield$427K
- Drew SodaNew Hope$220K
- Angela KapalkoPhiladelphia$123K
- Linda PerryPhiladelphia$123K
- Cory DavidsonErie$119K
- Shelley SassamanTamaqua$90K
- Meghan HoffnerBethlehem$86K
- Thomas IacovoniDanville$72K
- Scott CoxWynnewood$66K
- Sarah SmithPhiladelphia$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.